Evinacumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Angiopoietin-like 3 (ANGPTL3) |
| Clinical data | |
| Trade names | Evkeeza |
| Other names | REGN1500, evinacumab-dgnb |
| AHFS/Drugs.com | Evkeeza |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6480H9992N1716O2042S46 |
| Molar mass | 146083.95 g·mol−1 |
Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).[4][5][6]
Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials.[5]
Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).[5] ANGPTL3 slows the function of certain enzymes that break down fats in the body.[5] Evinacumab blocks ANGPTL3, allowing faster break down of fats that lead to high cholesterol.[5] Evinacumab was approved for medical use in the United States in February 2021.[5][9][10] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[11]
History
[edit]Regeneron invented evinacumab.[12]
The effectiveness and safety of evinacumab were evaluated in a double-blind, randomized, placebo-controlled, 24-week trial enrolling 65 participants with homozygous familial hypercholesterolemia (HoFH).[5] In the trial, 43 participants received 15 mg/kg of evinacumab every four weeks and 22 participants received the placebo.[5] Participants were taking other lipid-lowering therapies as well.[5] The trial was conducted in the United States, Italy, France, Greece, Netherlands, Austria, Canada, Australia, New Zealand, Ukraine, South Africa, and Japan.[6]
The primary measure of effectiveness was the percent change in low-density lipoprotein (LDL-C) from the beginning of treatment to week 24.[5] At week 24, participants receiving evinacumab had an average 47% decrease in LDL-C while participants on the placebo had an average 2% increase.[5]
The U.S. Food and Drug Administration (FDA) granted the application for evinacumab orphan drug, breakthrough therapy, and priority review designations.[5][11] The FDA granted approval of Evkeeza to Regeneron Pharmaceuticals, Inc.[5]
Society and culture
[edit]Legal status
[edit]In April 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Evkeeza, intended for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).[7] The applicant for this medicinal product is Regeneron Ireland Designated Activity Company (DAC).[7] Evinacumab was approved for medical use in the European Union in June 2021.[7]
References
[edit]- ^ "Details for: Evkeeza". Health Canada. 21 November 2023. Retrieved 3 March 2024.
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
- ^ "Summary Basis of Decision (SBD) for Evkeeza". Health Canada. 8 February 2024. Retrieved 24 February 2024.
- ^ a b "Evkeeza- evinacumab injection, solution, concentrate". DailyMed. Retrieved 14 September 2021.
- ^ a b c d e f g h i j k l m n This article incorporates text from this source, which is in the public domain.
- ^ a b c This article incorporates text from this source, which is in the public domain.
- ^ a b c d "Evkeeza EPAR". European Medicines Agency (EMA). 21 April 2021. Retrieved 18 December 2021.
- ^ "Evkeeza Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "FDA Approves First-in-class Evkeeza (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol" (Press release). Regeneron Pharmaceuticals. 11 February 2021. Retrieved 12 February 2021 – via PR Newswire.
- ^ "Drug Approval Package: Evkeeza". U.S. Food and Drug Administration (FDA). 11 March 2021. Retrieved 13 September 2021.
- ^ a b This article incorporates text from this source, which is in the public domain.
- ^ "FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol". Regeneron Pharmaceuticals Inc. (Press release). Retrieved 30 August 2021.
Further reading
[edit]- Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, et al. (July 2017). "Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease". N Engl J Med. 377 (3): 211–221. doi:10.1056/NEJMoa1612790. PMC 5800308. PMID 28538136.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.